Integra LifeSciences Reports Second Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
BTIG Downgrades Integra LifeSciences (IART) to Sell
July 29, 2024 4:10 PM EDTBTIG analyst Ryan Zimmerman downgraded Integra LifeSciences (NASDAQ: IART) from Neutral to Sell with a price target of $22.00.
The analyst comments "We are downgrading to SELL following 2Q24 results, setting a $22 PT at 8.5x our 12-24 month EPS estimate. Another quarter and another negative update regarding IART's manufacturing and quality controls pushing out recovery to FY26. At the same time, IART's 2Q24 results were not bad. IART reported rev. of $418.2M (9.7%, 2.3% organic, 0.3% organic ex. Boston) and adj. EPS... More
